Headlines

Novo Nordisk’s semaglutide shows additional cardiovascular benefits in overweight patients

Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and obese adults with heart disease.

FDA grants accelerated approval to Novartis’ Scemblix as a first-line leukemia therapy

Scemblix is the first drug to show superiority over all standard of care therapies for a rare type of leukemia.

Paid for and in partnership with Lonza Small Molecules

Streamlining early phase drug development with continuous flow technologies

Lonza’s innovative continuous flow technology and mini-monoplant approach are transforming early-phase drug development. How can they accelerate timelines and reduce costs?

Axonis raises $115 million to overcome drug resistance in epilepsy

The Boston-based startup Axonis Therapeutics has bagged $115 million in a Series A round to fuel its pipeline of treatments for pain, epilepsy and other conditions.

GLP-1 market heats up as companies vie for next-gen obesity drugs

Competitors race to launch GLP-1 drugs amid soaring weight loss demand

Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are the companies racing for approval of their own versions of these highly coveted drugs.

GSK beefs up US manufacturing site with $800 million investment

The big pharma company GlaxoSmithKline will inject up to $800 million into its manufacturing site in Marietta, Pennsylvania, to double its size and capacity.

Rentschler Biopharma expands CDMO facilities in Germany

The expansion will involve the construction of a new buffer media facility and represents the largest investment from Rentschler at its Germany headquarters.

Merck acquires cancer startup in a deal worth up to $1.3 billion

Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair processes.

Radiopharmaceutical CDMO launched by NorthStar Medical Radioisotopes

The US manufacturer NorthStar Medical Radioisotopes has unveiled a Contract Development & Manufacturing (CDMO) facility dedicated to the production and development of medical radioisotopes.